(Q37835834)

24 August 2017

1 reference

title

Antibody-mediated rejection in kidney transplantation: an update (English)

1 reference

24 August 2017

1 reference

kidney transplantation

1 reference

Jessica G Lucas

1

1 reference

24 August 2017

Jeannie P Co

2

1 reference

24 August 2017

Uzoamaka T Nwaogwugwu

3

1 reference

24 August 2017

Imran Dosani

4

1 reference

24 August 2017

Kalathil K Sureshkumar

5

1 reference

24 August 2017

language of work or name

English

0 references

publication date

5 February 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

579-592

1 reference

Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

"Hyperacute" renal-homograft rejection in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Differential outcomes in 3 types of acute antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Predicting kidney graft failure by HLA antibodies: a prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Antibody to human leukocyte antigen triggers endothelial exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Antibody-mediated rejection: treatment alternatives and outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Antibody-mediated rejection following renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Successful rescue therapy with plasmapheresis and intravenous immunoglobulin for acute humoral renal transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Novel rescue therapy for C4d-positive acute humoral renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Mycophenolate mofetil: how to further improve using an already successful drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Rituximab as treatment for refractory kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Impact of rituximab therapy for treatment of acute humoral rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Proteasome inhibition reduces donor-specific antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Abrogation of anti-HLA antibodies via proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Deciphering antibody-mediated rejection: new insights into mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

The effect of desensitization protocols on human splenic B-cell populations in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.525219

10.1517/14656566.2011.525219

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference